Effect of pharmacy management on turnaround time of 4-factor prothrombin complex concentrate

被引:4
作者
Langstraat, Eileen [1 ]
Martinelli, Ashley [2 ]
Spoelhof, Brian [3 ]
Shah, Shailly [4 ]
机构
[1] Kaiser Permanente, Dept Pharm, Rockville, MD USA
[2] Univ Maryland, Med Ctr, Dept Pharm, Baltimore, MD 21201 USA
[3] Lahey Hosp, Dept Pharm, Burlington, MA USA
[4] Emory Univ, Hosp Midtown, Dept Pharm, Atlanta, GA 30322 USA
关键词
blood coagulation factors; hospital medication errors; prothrombin complex concentrates; warfarin; EMERGENT WARFARIN REVERSAL; K ANTAGONIST REVERSAL; INTRACRANIAL HEMORRHAGE; MORTALITY; 3-FACTOR; PLASMA;
D O I
10.2146/ajhp160698
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose. The change in turnaround time of 4-factor prothrombin complex concentrate (PCC) when managed by the pharmacy department compared to blood bank management was evaluated. Methods. A retrospective analysis evaluated blood bank versus pharmacy management of PCC. Blood bank management was evaluated from November 2014 to November 2015, and pharmacy management was evaluated from December 2015 to July 2016. Chart review was performed on all patients who received PCC during these study periods. The primary outcome was the difference in median time from order entry to administration between management groups. Comparisons were made for the appropriateness of clinical use, length of stay, and discharge status. The primary outcome was analyzed using a Mann-Whitney U test. Secondary outcomes were analyzed using the chi-square test or Fisher's exact test. Descriptive statistics were utilized to analyze secondary outcomes. Results. Forty-three patients received PCC in the blood bank group, and 22 patients received PCC in the pharmacy group. Median turnaround time of PCC was lower in the pharmacy group (43 minutes; interquartile range [IQR], 32-65 minutes) compared to the blood bank group (62 minutes; IQR; 39-110 minutes; p = 0.032). PCC use was clinically appropriate for 55% of patients (n = 12) in the pharmacy group compared with 37% of patients (n = 16) in the blood bank group (p = 0.182). There were no significant differences between the blood bank and pharmacy groups with regard to hospital length of stay or in-hospital mortality. Conclusion. Conversion of PCC management from the blood bank to the pharmacy was associated with a significant decrease in time to PCC administration.
引用
收藏
页码:S61 / S66
页数:6
相关论文
共 18 条
[1]   Fixed Versus Variable Dosing of Prothrombin Complex Concentrate in Vitamin K Antagonist-Related Intracranial Hemorrhage: A Retrospective Analysis [J].
Abdoellakhan, Rahat Amadkhan ;
Miah, Ishita Parveen ;
Khorsand, Nakisa ;
Meijer, Karina ;
Jellema, Korne .
NEUROCRITICAL CARE, 2017, 26 (01) :64-69
[2]   EVALUATION OF WARFARIN REVERSAL WITH 4-FACTOR PROTHROMBIN COMPLEX CONCENTRATE COMPARED TO 3-FACTOR PROTHROMBIN COMPLEX CONCENTRATE AT A TERTIARY ACADEMIC MEDICAL CENTER [J].
Al-Majzoub, Omar ;
Rybak, Eva ;
Reardon, David P. ;
Krause, Patricia ;
Connors, Jean M. .
JOURNAL OF EMERGENCY MEDICINE, 2016, 50 (01) :7-13
[3]  
[Anonymous], 2013, KCENTR PROTHR COMPL
[4]  
Frontera JA, 2016, NEUROCRIT CARE, V24, P6, DOI 10.1007/s12028-015-0222-x
[5]   Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial [J].
Goldstein, Joshua N. ;
Refaai, Majed A. ;
Milling, Truman J., Jr. ;
Lewis, Brandon ;
Goldberg-Alberts, Robert ;
Hug, Bruce A. ;
Sarode, Ravi .
LANCET, 2015, 385 (9982) :2077-2087
[6]   Evidence-Based Management of Anticoagulant Therapy Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [J].
Holbrook, Anne ;
Schulman, Sam ;
Witt, Daniel M. ;
Vandvik, Per Olav ;
Fish, Jason ;
Kovacs, Michael J. ;
Svensson, Peter J. ;
Veenstra, David L. ;
Crowther, Mark ;
Guyatt, Gordon H. .
CHEST, 2012, 141 (02) :E152S-E184S
[7]   Rapid warfarin reversal in anticoagulated patients with traumatic intracranial hemorrhage reduces hemorrhage progression and mortality [J].
Ivascu, FA ;
Howells, GA ;
Junn, FS ;
Bair, HA ;
Bendick, PJ ;
Janczyk, RJ .
JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE, 2005, 59 (05) :1131-1137
[8]   3-Factor Versus 4-Factor Prothrombin Complex Concentrate for Warfarin Reversal in Severe Bleeding: A Multicenter, Retrospective, Propensity-Matched Pilot Study [J].
Jones, G. Morgan ;
Erdman, Michael J. ;
Smetana, Keaton S. ;
Mohrien, Kerry M. ;
Vandigo, Joseph E. ;
Elijovich, Lucas .
JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2016, 42 (01) :19-26
[9]   An observational, prospective, two-cohort comparison of a fixed versus variable dosing strategy of prothrombin complex concentrate to counteract vitamin K antagonists in 240 bleeding emergencies [J].
Khorsand, Nakisa ;
Veeger, Nic J. G. M. ;
van Hest, Reinier M. ;
Ypma, Paula F. ;
Heidt, Jeroen ;
Meijer, Karina .
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (10) :1501-1506
[10]   Evaluation of fixed dose 4-factor prothrombin complex concentrate for emergent warfarin reversal [J].
Klein, Lauren ;
Peters, Jessica ;
Miner, James ;
Gorlin, Jed .
AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2015, 33 (09) :1213-1218